NICE Tarceva Restrictions ‘Leave NSCLC Patients Without Options,’ Roche Says
This article was originally published in The Pink Sheet Daily
Executive Summary
NICE has cleared Roche’s Tarceva as second-line therapy but restricted its indication so severely that it barely puts it ahead of a competing pack of NSCLC therapies – and effectively cuts options for patients.